SLC5A2 and hydrops fetalis: A recent meta-analysis of these two trials reported that in patients with a broad spectrum of HFrEF severity, SGLT2 inhibition with empagliflozin or dapagliflozin, on top of guideline-directed medical therapy, reduced all-cause and cardiovascular death, HF hospitalisations and serious adverse renal outcomes, without heterogeneity between the two trials [12].